Starboard Value, which recently took a $1bn stake in Pfizer, has claimed “coercive conduct” following a U-turn from two former executives who had originally supported its vision to turn profits at the drugmaker. Click here for the full article - https://lnkd.in/dMitGJHf #pharma #pfizer
Pharmaceutical-Technology
Internet News
London , England 2,384 followers
The leading site for data driven news in the pharmaceutical industry. Part of GlobalData
About us
Pharmaceutical-technology.com is one of a network of 30+ proprietary B2B websites, with an unrivalled global audience of active decision makers, influencers, and opinion leaders across the world with a combined readership of 55 million industry professionals each year. As part of GlobalData, we have access to over 1bn data points including companies, deals, projects and forecasts and trends. Leading data informs and supports our industry leading content. With expertise spanning more than 80 markets globally and driven by 800+ award-winning journalists, researchers, and analysts, we connect you with the information that makes and breaks businesses every day. Combined with our award-winning targeting technology built into our network of websites, we offer a unique end-to-end marketing solution combining insight, creativity, and cutting-edge AI-technology. Our marketing solution allows clients to identify, target and engage with prospects using access and ownership of our 30+ B2B media websites and their large sector specific audiences. With more reach, data targeting and first-party data than any other partner, we produce world-class campaigns for our clients. For more details on our technology-driven marketing solution visit www.globaldatamarketingsolutions.com
- Website
-
www.pharmaceutical-technology.com
External link for Pharmaceutical-Technology
- Industry
- Internet News
- Company size
- 501-1,000 employees
- Headquarters
- London , England
- Type
- Public Company
Locations
-
Primary
John Carpenter Street
John Carpenter House
London , England EC4Y 0AN, GB
Updates
-
Gummies have become the second best-selling delivery model in all of vitamins, mineral and supplements (VMS) space, said Mitchell Slade, President at PL Developments Gummy Co, at the ongoing CPHI Europe conference. Click here for the full article - #drugdelivery #CPHIEurope #pharma #gummies
-
Eli Lilly and Company has teamed up with insitro to develop treatments for metabolic diseases, combining insitro’s artificial intelligence (AI) machine learning (ML) platform with Lilly’s drug delivery technology. insitro’s CEO Daphne Koller highlighted the potential of the company’s platform to address metabolic disease at its origin using its technology. “Our proprietary AI/ML platform, leveraging multimodal data at scale, computational power, and genetics, has identified several high-value targets with extensive support in human genetics and translatable models.” Click here for the full article - https://lnkd.in/dK8JX3x9 #pharma #siRNA #metabolicdrugs #aiinhealthcare #drugdelivery
-
Boehringer Ingelheim and Circle Pharma, Inc. have entered a new research partnership and licence agreement to develop a new precision cancer treatment. Boehringer Ingelheim discovery research senior vice-president and global head Clive Wood stated: “We’re delighted to be joining forces with Circle’s scientists to develop an innovative cancer treatment based on their proprietary macrocycle platform molecules to achieve our goal of transforming the lives of people living with cancer. This new collaboration complements our oncology research portfolio, and further reinforces our commitment to tackling intractable targets.” Click here for the full article - https://lnkd.in/dxTXhacx #clinicalresearch #cancertreatment #oncology #pharma
-
🎯 2025 Media Planning is in full swing! GlobalData Marketing Solutions harnesses data to provide award winning content creation and targeted lead generation through our industry leading b2b Pharmaceutical website. 👉 Click below to view our new media kit. - https://lnkd.in/gZbX_6Hg If you would like to have a demo of the solution please send us a message or request a demo here: https://lnkd.in/e8wNB3cj #pharma #drugdevelopment #drugdiscovery #CDMO #CRO #drugmanufacturing #healthcaremarketing #lifesciencemarketing #medicalmarketing #abm #accountbasedmarketing #datamarketing
-
In an era where pharmaceutical safety and regulatory compliance are critical, Syngene International Limited stands out as a leader in comprehensive nitrosamine testing. Syngene not only provides cutting-edge analytical services but also offers a holistic approach, integrating risk assessment, impurity profiling, and regulatory support. With its end-to-end capabilities, Syngene helps pharmaceutical companies navigate the complexities of nitrosamine contamination while upholding the highest standards of patient safety. As the industry faces ongoing challenges with nitrosamine impurities, Syngene’s agile solutions deliver excellence and reliability in the global pharmaceutical landscape. Find out more - https://lnkd.in/eBdRfRry #PharmaceuticalSafety #NitrosamineTesting #SyngeneInternational #RegulatoryCompliance #PatientSafety
Syngene Company Insight - Pharma Technology Focus | Issue 148 | November 2024
pharma.nridigital.com
-
As a major report highlights the challenges of a struggling NHS, the call for preventative care is growing in the UK. With a taskforce investigating ways of integrating preventative health services into communities, and a powerful case finding solution now available to put proactive care into action, we explore the latest in preventative health innovation. Click here for the full article from EMIS - https://lnkd.in/dPyKMNrq #NHS #UKhealthcare #pharma #healthcare #preventativecare
-
Anima Biotech is utilising machine learning (ML) to investigate the role of messenger RNA (mRNA) in disease, revealing previously unseen pathophysiologies and honing in on new therapies. Anima’s CEO Yochi Slonim told Pharmaceutical-Technology in an exclusive interview how preclinical studies have shown this candidate significantly reduced inflammation and fibrosis in affected cells. The effect was greater than seen with Boehringer Ingelheim’s Ofev (nintedanib), the current standard-of-care for IPF. Anima’s candidate also inhibited collagen deposition and fibrotic markers significantly, as per a February 2024 release. Click here for the full article - https://lnkd.in/gP6M6MjT #pharma #clinicaltrials #mRNA #machinelearning #ai #aiinhealthcare #RNA
-
Rephine, global experts in quality assurance & GxP compliance across pharmaceutical, biotech & medical device manufacturing supply chains will be exhibiting at CPHI Worldwide 2024 in Milan. Attendees can visit Stand 2F41 in the API Zone from 8-10 to meet there team of experts and explore the latest in audit management, digital transformation, GxP compliance, and QMS solutions. Click here to learn more - https://lnkd.in/dfPzFBVs #pharma #biotech #CPHI #medicaldevice #GxP #qualityassurance
-
Syngene International Limited, a global leader in integrated research, development, and manufacturing services, will be exhibiting at CPHI Worldwide 2024 in Milan. Attendees can visit Booth #7C114 from October 8-10 to explore Syngene's end-to-end solutions. With over 30 years of experience, 400+ global clients, and more than 400 patents held with clients, Syngene continues to drive innovation in biopharma. Find out more - https://lnkd.in/ekdz4YGB #CPHIWorldwide #SyngeneInternational #Biopharma
Syngene - Pharma Technology Focus | Issue 148 | November 2024
pharma.nridigital.com